Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Instagram Outage Disrupts Thousands of U.S. Users 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
HAUPPAUGE, N.Y., March 22, 2018 -- United-Guardian, Inc., (NASDAQ:UG) reported today that net income for FY-2017 increased by 49% over the previous year, rising from $2,581,142 ($0.56 per share) in 2016 to $3,844,290 ($0.84 per share) in 2017. Sales for the year were up from $11,144,462 in 2016 to $13,434,460 in 2017, an increase of 21%.
Ken Globus, President of United-Guardian, stated, “We had a significant increase in both sales and earnings in 2017, which was the result of both a 40% increase in sales of our cosmetic ingredients and an 18% increase in sales of our most important pharmaceutical product, Renacidin® Irrigation. The increase in sales of our cosmetic ingredients was due primarily to renewed sales of one of our Lubrajel® products in China, and the increase in Renacidin sales was mainly the result of this being the first full fiscal year of sales of our new single-dose form of that product. We have retained a web consultant to assist us in expanding our marketing efforts for Renacidin via our new Renacidin web site (www.renacidin.com). With some of our new “natural” cosmetic ingredients being actively promoted globally right now, as well as additional “natural” products in varying stages of development, we are optimistic that we will be able to further expand sales of both our cosmetic ingredients and Renacidin as the year progresses.”
United-Guardian is a manufacturer of cosmetic ingredients, personal and health care products, pharmaceuticals, and specialty industrial products.
Contact: Robert S. Rubinger
(631) 273-0900
NOTE: This press release contains both historical and "forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements about the company’s expectations or beliefs concerning future events, such as financial performance, business prospects, and similar matters, are being made in reliance upon the “safe harbor” provisions of that Act. Such statements are subject to a variety of factors that could cause the company’s actual results or performance to differ materially from the anticipated results or performance expressed or implied by such forward-looking statements. For further information about the risks and uncertainties that may affect the company’s business please refer to the company's reports and filings with the Securities and Exchange Commission.
FINANCIAL RESULTS FOR THE YEARS ENDED
DECEMBER 31, 2017 AND DECEMBER 31, 2016
STATEMENTS OF INCOME
| Years ended December 31, | ||||||
| 2017 | 2016 | |||||
| Sales: | ||||||
| Gross Sales | $ | 13,434,460 | $ | 11,144,462 | ||
| Sales allowances and returns | (466,255 | ) | (367,595 | ) | ||
| Net sales | 12,968,205 | 10,776,867 | ||||
| Costs and expenses: | ||||||
| Cost of sales | 5,301,352 | 4,882,644 | ||||
| Operating expenses | 1,785,160 | 1,852,833 | ||||
| Research and development | 646,079 | 651,828 | ||||
| Total costs and expenses | 7,732,591 | 7,387,305 | ||||
| Income from operations | 5,235,614 | 3,389,562 | ||||
| Investment income | 315,165 | 306,505 | ||||
| Income before provision for income taxes | 5,550,779 | 3,696,067 | ||||
| Provision for income taxes | 1,706,489 | 1,114,925 | ||||
| Net income | $ | 3,844,290 | $ | 2,581,142 | ||
| Earnings per common share (basic and diluted) | $ | 0.84 | $ | 0.56 | ||
| Weighted average shares (basic and diluted) | 4,594,319 | 4,594,319 | ||||
BALANCE SHEET DATA
(condensed)
| December 31, | ||||||
| 2017 | 2016 | |||||
| Current assets | $ | 11,850,522 | $ | 13,714,172 | ||
| Net property, plant, and equipment | 942,887 | 1,090,591 | ||||
| Deferred income taxes (net) | --- | 2,382 | ||||
| Other assets (net) | 59,471 | 59,295 | ||||
| Total assets | 12,852,880 | 14,866,440 | ||||
| Current liabilities | 1,422,383 | 1,045,951 | ||||
| Deferred income taxes (net) | 33,855 | --- | ||||
| Total Liabilities | 1,456,238 | 1,045,951 | ||||
| Stockholders’ equity | 11,396,642 | 13,820,489 | ||||
| Total liabilities and stockholders’ equity | $ | 12,852,880 | $ | 14,866,440 | ||
